Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etoricoxib vs Celecoxib in Osteoarthritis (Study 1)
NCT00092768Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2004
- Primary completion
- Feb 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of etoricoxib in osteoarthritis (OA) (3 arms), sponsored by Organon & Co. Primary endpoints: Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale at 12 weeks, Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Physical Function Subscale at 12 weeks and 4 more. Started Mar 2004; status: completed.
02
Drugs
etoricoxib
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00092768.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092768.